{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:43:19Z","timestamp":1782366199157,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701606"],"award-info":[{"award-number":["81701606"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00011-022-01581-3","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T09:03:08Z","timestamp":1656666188000},"page":"963-975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["IL-38, a potential therapeutic agent for lupus, inhibits lupus progression"],"prefix":"10.1007","volume":"71","author":[{"given":"Wang-Dong","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Chong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Yu","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Fang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"1581_CR1","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3389\/fimmu.2018.01462","volume":"9","author":"WD Xu","year":"2018","unstructured":"Xu WD, Huang AF. Role of interleukin-38 in chronic inflammatory diseases: a comprehensive review. Front Immunol. 2018;9:1462.","journal-title":"Front Immunol"},{"issue":"22","key":"1581_CR2","doi-asserted-by":"publisher","first-page":"12552","DOI":"10.3390\/ijms222212552","volume":"22","author":"A Esmaeilzadeh","year":"2021","unstructured":"Esmaeilzadeh A, Bahmaie N, Nouri E, Hajkazemi MJ, Zareh RM. Immunobiological properties and clinical applications of interleukin-38 for immune-mediated disorders: a systematic review study. Int J Mol Sci. 2021;22(22):12552.","journal-title":"Int J Mol Sci"},{"key":"1581_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109773","volume":"75","author":"Y Han","year":"2020","unstructured":"Han Y, Huard A, Mora J, da Silva P, Br\u00fcne B, Weigert A. IL-36 family cytokines in protective versus destructive inflammation. Cell Signal. 2020;75: 109773.","journal-title":"Cell Signal"},{"key":"1581_CR4","first-page":"7933453","volume":"2021","author":"Z Hao","year":"2021","unstructured":"Hao Z, Liu Y. IL-38 and IL-36 target autophagy for regulating synoviocyte proliferation, migration, and invasion in rheumatoid arthritis. Dis Markers. 2021;2021:7933453.","journal-title":"Dis Markers"},{"issue":"10","key":"1581_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1089\/jir.2021.0047","volume":"41","author":"L Huang","year":"2021","unstructured":"Huang L, Zhang H, Zhao D, Hu H, Lu Z. Interleukin-38 suppresses cell migration and proliferation and promotes apoptosis of colorectal cancer cell through negatively regulating extracellular signal-regulated kinases signaling. J Interferon Cytokine Res. 2021;41(10):375\u201384.","journal-title":"J Interferon Cytokine Res"},{"issue":"21","key":"1581_CR6","doi-asserted-by":"publisher","first-page":"12379","DOI":"10.1111\/jcmm.15737","volume":"24","author":"WD Xu","year":"2020","unstructured":"Xu WD, Su LC, Liu XY, et al. IL-38: a novel cytokine in systemic lupus erythematosus pathogenesis. J Cell Mol Med. 2020;24(21):12379\u201389.","journal-title":"J Cell Mol Med"},{"key":"1581_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2018.09.028","volume":"65","author":"WD Xu","year":"2018","unstructured":"Xu WD, Su LC, He CS, Huang AF. Plasma interleukin-38 in patients with rheumatoid arthritis. Int Immunopharmacol. 2018;65:1\u20137.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"1581_CR8","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s10067-017-3811-6","volume":"36","author":"EC Freitas","year":"2017","unstructured":"Freitas EC, de Oliveira MS, Monticielo OA. Pristane-induced lupus: considerations on this experimental model. Clin Rheumatol. 2017;36(11):2403\u201314.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"1581_CR9","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1581_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/sj.ki.5002118","volume":"71","author":"GS Markowitz","year":"2007","unstructured":"Markowitz GS, D\u2019Agati VD. The ISN\/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 2007;71(6):491\u20135.","journal-title":"Kidney Int"},{"issue":"24","key":"1581_CR11","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.1073\/pnas.92.24.10934","volume":"92","author":"M Satoh","year":"1995","unstructured":"Satoh M, Kumar A, Kanwar YS, Reeves WH. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB\/c mice treated with pristane. Proc Natl Acad Sci USA. 1995;92(24):10934\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"1581_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.it.2009.06.003","volume":"30","author":"WH Reeves","year":"2009","unstructured":"Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009;30(9):455\u201364.","journal-title":"Trends Immunol"},{"issue":"8","key":"1581_CR13","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/art.40863","volume":"71","author":"R Fu","year":"2019","unstructured":"Fu R, Xia Y, Li M, et al. Pim-1 as a therapeutic target in lupus nephritis. Arthritis Rheumatol. 2019;71(8):1308\u201318.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1581_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000510915","volume":"30","author":"M Zarrabi","year":"2021","unstructured":"Zarrabi M, Nazarinia M, Rahimi Jaberi A, Gholijani N, Amirghofran Z. Elevated IL-38 serum levels in newly diagnosed multiple sclerosis and systemic sclerosis patients. Med Princ Pract. 2021;30(2):146\u201353.","journal-title":"Med Princ Pract"},{"key":"1581_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154963","volume":"127","author":"C Xie","year":"2020","unstructured":"Xie C, Yan W, Quan R, et al. Interleukin-38 is elevated in inflammatory bowel diseases and suppresses intestinal inflammation. Cytokine. 2020;127: 154963.","journal-title":"Cytokine"},{"key":"1581_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.molimm.2020.09.006","volume":"127","author":"D Luo","year":"2020","unstructured":"Luo D, Chen Y, Zhou N, Li T, Wang H. Blockade of Th17 response by IL-38 in primary Sjogren\u2019s syndrome. Mol Immunol. 2020;127:107\u201311.","journal-title":"Mol Immunol"},{"issue":"12","key":"1581_CR17","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1002\/art.39328","volume":"67","author":"I Rudloff","year":"2015","unstructured":"Rudloff I, Godsell J, Nold-Petry CA, et al. Brief report: interleukin-38 exerts anti-inflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(12):3219\u201325.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1581_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.imbio.2016.10.012","volume":"222","author":"M Chu","year":"2017","unstructured":"Chu M, Tam LS, Zhu J, et al. In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)\/lpr mice. Immunobiology. 2017;222(3):483\u201393.","journal-title":"Immunobiology"},{"issue":"7","key":"1581_CR19","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/molecules21070933","volume":"21","author":"M Chu","year":"2016","unstructured":"Chu M, Chu IM, Yung EC, et al. Aberrant expression of novel cytokine IL-38 and regulatory T lymphocytes in childhood asthma. Molecules. 2016;21(7):933.","journal-title":"Molecules"},{"issue":"2","key":"1581_CR20","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1111\/jcmm.14902","volume":"24","author":"Y Ge","year":"2020","unstructured":"Ge Y, Huang M, Wu Y, Dong N, Yao YM. Interleukin-38 protects against sepsis by augmenting immunosuppressive activity of CD4(+) CD25(+) regulatory T cells. J Cell Mol Med. 2020;24(2):2027\u201339.","journal-title":"J Cell Mol Med"},{"key":"1581_CR21","doi-asserted-by":"publisher","first-page":"4927530","DOI":"10.1155\/2016\/4927530","volume":"2016","author":"KR Sigdel","year":"2016","unstructured":"Sigdel KR, Duan L, Wang Y, et al. Serum cytokines Th1, Th2, and Th17 expression profiling in active lupus nephritis-IV: from a Southern Chinese Han population. Mediators Inflamm. 2016;2016:4927530.","journal-title":"Mediators Inflamm"},{"key":"1581_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cytogfr.2018.12.001","volume":"45","author":"YM Mao","year":"2019","unstructured":"Mao YM, Zhao CN, Leng J, et al. Interleukin-13: a promising therapeutic target for autoimmune disease. Cytokine Growth Factor Rev. 2019;45:9\u201323.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"1581_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41392-020-0139-5","volume":"5","author":"ZX Xiao","year":"2020","unstructured":"Xiao ZX, Hu X, Zhang X, et al. High salt diet accelerates the progression of murine lupus through dendritic cells via the p38 MAPK and STAT1 signaling pathways. Signal Transduct Target Ther. 2020;5(1):34.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1581_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.autrev.2018.08.010","volume":"18","author":"A Goropev\u0161ek","year":"2019","unstructured":"Goropev\u0161ek A, Holcar M, Pahor A, Av\u010din T. STAT signaling as a marker of SLE disease severity and implications for clinical therapy. Autoimmun Rev. 2019;18(2):144\u201354.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1581_CR25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41423-019-0300-7","volume":"17","author":"X Sun","year":"2020","unstructured":"Sun X, Hou T, Cheung E, et al. Anti-inflammatory mechanisms of the novel cytokine interleukin-38 in allergic asthma. Cell Mol Immunol. 2020;17(6):631\u201346.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1581_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41419-020-03283-2","volume":"12","author":"X Gao","year":"2021","unstructured":"Gao X, Chan PKS, Lui GCY, et al. Interleukin-38 ameliorates poly(I:C) induced lung inflammation: therapeutic implications in respiratory viral infections. Cell Death Dis. 2021;12(1):53.","journal-title":"Cell Death Dis"},{"key":"1581_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106592","volume":"85","author":"H Yu","year":"2020","unstructured":"Yu H, Liu Y, Xie W, Xie Q, Liu Q, Cheng L. IL-38 alleviates the inflammatory response and the degeneration of nucleus pulposus cells via inhibition of the NF-\u03baB signaling pathway in vitro. Int Immunopharmacol. 2020;85: 106592.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"1581_CR28","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41423-020-00540-4","volume":"18","author":"K Ma","year":"2021","unstructured":"Ma K, Du W, Xiao F, et al. IL-17 sustains the plasma cell response via p38-mediated Bcl-xL RNA stability in lupus pathogenesis. Cell Mol Immunol. 2021;18(7):1739\u201350.","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"1581_CR29","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/art.30392","volume":"63","author":"LF Hou","year":"2011","unstructured":"Hou LF, He SJ, Li X, et al. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL\/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum. 2011;63(8):2445\u201355.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1581_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/BOR.0000000000000777","volume":"33","author":"A Chang","year":"2021","unstructured":"Chang A, Clark MR, Ko K. Cellular aspects of the pathogenesis of lupus nephritis. Curr Opin Rheumatol. 2021;33(2):197\u2013204.","journal-title":"Curr Opin Rheumatol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-022-01581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-022-01581-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-022-01581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T07:11:08Z","timestamp":1658473868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-022-01581-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":30,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1581"],"URL":"https:\/\/doi.org\/10.1007\/s00011-022-01581-3","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"assertion":[{"value":"29 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved Animal Ethics Committee of Southwest Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}